Sanofi - STAT

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Sanofi moves to replace the Medivation board

Pharmalot By Ed Silverman

Sanofi revamps top management, chief diabetes exec to leave

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Sanofi threatens to launch a hostile bid for Medivation

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Medivation rejects Sanofi’s $9.3 billion bid as ‘undervalued’

Pharmalot By Ed Silverman

A frustrated Sanofi makes $9.3 billion bid for Medivation and its cancer drug

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Sanofi poaches a top scientist from AstraZeneca

Health By Helen Branswell

Sanofi science chief says it’s time to ‘think big’ about global epidemics like Zika

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Some investors losing confidence in Valeant, Sanofi abandoning allergy med

Pharmalot By Ed Silverman

Q&A: A jump-start on Zika vaccine, but will still take ‘some years’

Pharmalot By Ed Silverman

Sanofi layoffs expected as reorganization goes into effect

Pharmalot By Ed Silverman

Breathe deeply: Sanofi will no longer market Afrezza inhaled insulin

Business By Karen Weintraub

From the ivory tower to the corner office, academics infuse new life into pharma

Business By Andrew Joseph

Most Read

Prescription apps are gaining ground — and drug makers’ backing — as digital therapeutics

What clinical trial results? Now you can see who isn’t sharing their findings

Pfizer stops developing a cholesterol drug. So who is the big winner?

The insulin market is heading for a shakeup. But patients may not benefit

New diabetes tech is coming. But will it make much difference?

Up and down the ladder: The latest comings and goings

Up and down the ladder: The latest comings and goings

Pharmalot, Pharmalittle: Conservative group runs ads to defeat Medicare Part B overhaul

All Coverage

Pharmalot, Pharmalittle: Sanofi moves to replace the Medivation board

Sanofi revamps top management, chief diabetes exec to leave

Up and down the ladder: The latest comings and goings

Pharmalot, Pharmalittle: Sanofi threatens to launch a hostile bid for Medivation

Pharmalot, Pharmalittle: Medivation rejects Sanofi’s $9.3 billion bid as ‘undervalued’

A frustrated Sanofi makes $9.3 billion bid for Medivation and its cancer drug

Up and down the ladder: The latest comings and goings

Pharmalot, Pharmalittle: Sanofi poaches a top scientist from AstraZeneca

Sanofi science chief says it’s time to ‘think big’ about global epidemics like Zika

Up and down the ladder: The latest comings and goings

Pharmalot, Pharmalittle: Some investors losing confidence in Valeant, Sanofi abandoning allergy med

Q&A: A jump-start on Zika vaccine, but will still take ‘some years’

Sanofi layoffs expected as reorganization goes into effect

Breathe deeply: Sanofi will no longer market Afrezza inhaled insulin

From the ivory tower to the corner office, academics infuse new life into pharma

Why drug makers share their prized compound libraries with competitors